Discussion
The European Medicines Agency (EMA) has accepted for review an application seeking approval of the experimental injection therapy obexelimab for people with  immunoglobulin G4-related disease (IgG4-RD). The agency confirmed that the Marketing Authorization Application (MAA) submitted by the therapy’s developer, Zenas Biopharma, contains all the required information…
